Helix, the leading population genomics company in the nation, announced that Hylton Kalvaria has joined its leadership team as senior vice president (SVP) of Life Sciences. Kalvaria will oversee partnerships leveraging the unique and growing clinico-genomic datasets of Helix with life sciences customers.
Kalvaria brings a wealth of executive experience and healthcare data expertise gleaned from more than a decade of holding positions of increasing responsibility within the life sciences industry. He was most recently President and Chief Commercial Officer at clinical natural language processing startup Mendel AI. Kalvaria also served in leadership roles at Verana Health, Flatiron Health, and Genentech.
“We’re thrilled with the momentum we’ve seen in 2023 and the start of 2024, finalizing partnerships with some of the top health systems, life sciences and public health organizations in the country,” said James Lu, MD, Ph.D., CEO and co-founder of Helix. “Strengthening our leadership team with someone as talented and passionate as Hylton only further positions Helix to ensure the power of genomics is used to improve healthcare outcomes on the largest possible scale.”
Also Read: Ibex and PathPresenter Launch Partnership to Accelerate Adoption of AI-powered Digital Pathology
For the last several years, Helix has been helping life science companies bring innovative, personalized therapies to patients faster through the application of their real-world clinico-genomic data and extensive health systems network. Helix’s comprehensive platform of solutions can be used to access data in a wide range of disease-specific clinico-genomic datasets to accelerate the drug development process from discovery to commercialization.
“I’m proud to be part of a company doing meaningful work that has the potential to affect positive change for all stakeholders in the healthcare ecosystem,” Hylton Kalvaria said. “The sheer number of new drugs in development that leverage genetic approaches is driving massive demand for the kinds of datasets that Helix has become known for. Helix is committed to partnering with life science companies to leverage real-world clinico-genomic data across the drug development lifecycle.”
SOURCE: BusinessWire
